ATE447969T1 - Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin - Google Patents

Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin

Info

Publication number
ATE447969T1
ATE447969T1 AT00984395T AT00984395T ATE447969T1 AT E447969 T1 ATE447969 T1 AT E447969T1 AT 00984395 T AT00984395 T AT 00984395T AT 00984395 T AT00984395 T AT 00984395T AT E447969 T1 ATE447969 T1 AT E447969T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
hemorrhagia
ischemia
antagonists
Prior art date
Application number
AT00984395T
Other languages
English (en)
Inventor
Jane Relton
Roy Lobb
Eric Whalley
Steve Adams
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE447969T1 publication Critical patent/ATE447969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00984395T 1999-12-16 2000-12-14 Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin ATE447969T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17126599P 1999-12-16 1999-12-16
PCT/US2000/033942 WO2001043774A1 (en) 1999-12-16 2000-12-14 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Publications (1)

Publication Number Publication Date
ATE447969T1 true ATE447969T1 (de) 2009-11-15

Family

ID=22623149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984395T ATE447969T1 (de) 1999-12-16 2000-12-14 Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin

Country Status (11)

Country Link
US (1) US20020197233A1 (de)
EP (3) EP2332578A1 (de)
JP (3) JP2003517023A (de)
AT (1) ATE447969T1 (de)
AU (1) AU783110B2 (de)
CA (1) CA2394431C (de)
DE (1) DE60043308D1 (de)
DK (2) DK1242118T3 (de)
ES (2) ES2415708T3 (de)
NZ (1) NZ519447A (de)
WO (1) WO2001043774A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
PT1214091E (pt) * 1999-09-14 2006-09-29 Imperial College Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
FR2827174B1 (fr) * 2001-07-13 2004-08-06 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
KR20050114212A (ko) 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
EP1624846A2 (de) * 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Hemmung der arzneimittelbindung an serumalbumin
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
RU2283108C2 (ru) * 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
ZA200606557B (en) 2004-02-06 2008-02-27 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
KR20070001976A (ko) * 2004-02-10 2007-01-04 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논 우레아
US8518021B2 (en) * 2004-05-27 2013-08-27 Baxter International Inc. Apparatus and method for therapeutic delivery of medication
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
WO2007041697A2 (en) * 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
EP3620469A1 (de) 2006-02-28 2020-03-11 Biogen MA Inc. Verfahren zur behandlung von entzündungs- und autoimmunerkrankungen mit natalizumab
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
ES2685802T3 (es) * 2006-05-25 2018-10-11 Biogen Ma Inc. Antagonista de VLA-1 para su utilización en el tratamiento de un accidente cerebrovascular
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2467159A1 (de) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 als biomarker zur prognose und target zur behandlung der duchenne-muskeldystrophie
EP4152004B9 (de) 2010-01-11 2025-04-09 Biogen MA Inc. Assay für jc-viren-antikörper
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
PL3575792T3 (pl) 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
CN103619874A (zh) * 2011-06-30 2014-03-05 株式会社免疫生物研究所 可溶性整联蛋白α4突变体
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP3004334A4 (de) 2013-05-28 2016-12-21 Biogen Ma Inc Verfahren zur beurteilung eines pml-risikos
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016149248A1 (en) * 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN121729428A (zh) 2023-05-30 2026-03-24 派拉冈医疗公司 α4β7整联蛋白抗体组合物和使用方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL47468A (en) 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5284756A (en) 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
KR100367948B1 (ko) * 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
AU8585198A (en) * 1997-07-31 1999-02-22 American Home Products Corporation Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
CA2327260A1 (en) * 1999-03-03 2000-09-08 Biogen, Inc. Methods of modulating lipid metabolism and storage
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
ES2335643T3 (es) 2010-03-31
JP2012167128A (ja) 2012-09-06
NZ519447A (en) 2004-03-26
AU783110B2 (en) 2005-09-22
EP2332578A1 (de) 2011-06-15
JP5519612B2 (ja) 2014-06-11
WO2001043774A1 (en) 2001-06-21
CA2394431A1 (en) 2001-06-21
EP1242118B1 (de) 2009-11-11
EP2140881B1 (de) 2013-04-17
EP2140881A1 (de) 2010-01-06
JP2003517023A (ja) 2003-05-20
DE60043308D1 (de) 2009-12-24
AU2102001A (en) 2001-06-25
DK2140881T3 (da) 2013-05-06
JP2012017345A (ja) 2012-01-26
ES2415708T3 (es) 2013-07-26
US20020197233A1 (en) 2002-12-26
CA2394431C (en) 2015-06-30
DK1242118T3 (da) 2010-01-11
EP1242118A1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
ATE447969T1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
DE602004010381D1 (de) Verfahren und vorrichtung zur behandlung von wasser für eine einpressbohrung
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE60115411D1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE60011918D1 (de) Vorrichtung und verfahren zur lokalen behandlung von wasser
DE69928237D1 (de) Verfahren zur behandlung von abwasser zur entfernung von organischen stoffen und stickstoff,
ATE164079T1 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE60104188D1 (de) Verfahren und vorrichtung zur behandlung von wasser/abwasser
ATE259245T1 (de) Verfahren zur behandlung von beweggungsstörungen
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
DE60120520D1 (de) Verfahren zur behandlung von abwasser
EP1507765A4 (de) Verfahren und zusammensetzungen zur behandlung von störungen des zentralen und peripheren nervensystems und hierfür geeignete neue verbindungen
ATE280744T1 (de) Verfahren zur herstellung von n-((aliphatisch oder aromatisch)carbonyl)-2-aminoacetamid- verbindungen und deren cyclisierung
DE50105285D1 (de) Verfahren und Vorrichtung zum Schwenken der Abteiler von mehrteiligen landwirtschaftlichen Erntemaschinen
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
ATE277997T1 (de) Verfahren zur stabilisierung von textilweichmacherzusammensetzungen
DE10084174T1 (de) Verfahren zur Verpackung von IC-Vorrichtungen, welche Hohlräume neben aktiven Gebieten enthalten, und verwandter Strukturen
DE59705243D1 (de) Verfahren zur Herstellung von N-substituierten cyclischen Aminen
EP1542702A4 (de) Verfahren und zusammensetzungen zur behandlung von neurologischen störungen
DE60018707D1 (de) Anti-androgene und verfahren zur behandlung von krankheiten
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
DE50104023D1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties